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Abstract
Aims Methods to identify patients at risk for incident HF would be welcome as such patients might beneﬁt from earlier
interventions.
Methods and results From a registry of 1251 patients referred for coronary and/or peripheral angiography, we sought to
identify independent predictors of incident HF during follow-up and develop a clinical and biomarker strategy to predict this
outcome. There were 991 patients free of prevalent HF at baseline. Cox proportional hazard models were developed to predict
adjudicated diagnosis of incident HF. Model discrimination and reclassiﬁcation were evaluated. At follow-up, 177 (18%) devel-
oped new-onset HF. Independent predictors of new-onset HF included ﬁve clinical variables (age, male sex, heart rate, history
of atrial ﬁbrillation/ﬂutter, and history of hypertension) and two biomarkers (amino-terminal pro-B type natriuretic peptide
and ST2). The c-statistic for the model without biomarkers was 0.69; including biomarkers increased the c-statistic to 0.76
(P < 0.001). A score was developed from the model. Patients in the highest score quintile had shortest time to incident HF
compared with lower quintiles (log-rank P< 0.001). Following 100 bootstrap iterations, internal validation was conﬁrmed with
Harrell’s c-statistic of 0.77. Use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and beta-blockers
at enrollment was associated with substantial attenuation of predictive value of the risk score.
Conclusions Patients undergoing coronary/peripheral angiographic procedures are a population at high risk for incident HF.
We describe an accurate clinical and biomarker strategy for predicting incident HF and possibly intervening in such patients
(NCT00842868).
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Introduction
HF is a complex disease process growing in prevalence, de-
spite ongoing efforts to curb its expansion. This rise in HF is
partially attributable to an aging population, improved care
of other forms of acute heart disease, and increasing preva-
lence of risk factors that contribute to the development of
HF.1 Despite advancements in treatment of those with
established HF, the impact of the diagnosis has continued
to increase with unacceptably high morbidity, mortality, and
cost;2–4 it is clear that a change in the approach to HF man-
agement is needed. One such change might be attempts to
better predict the onset of the diagnosis, with an eye towards
therapeutic interventions to reduce its incidence. Indeed, in
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comparison with efforts towards treating symptomatic forms
of HF, prevention of the diagnosis in at-risk patients remains
largely under-explored.
The American College of Cardiology and the American
Heart Association identify two groups of patients without
symptomatic HF but at risk for progression to symptoms;5
such patients with so-called Stage A or B HF (at-risk and
asymptomatic structural heart disease, respectively) appear
to beneﬁt from risk factor modiﬁcation to prevent progres-
sion to overt HF. However, the number of patients in these
stages of HF is massive, with broad heterogeneity in terms
of absolute risk for HF onset. Accordingly, researchers have
sought to develop tools to better reﬁne the ability to predict
new-onset HF in at-risk subjects;6,7 however, drawbacks to
these models include potential lack of portability and limita-
tion in variables incorporated, including concentrations of
cardiac biomarkers such as amino-terminal pro-B type natri-
uretic peptide (NT-proBNP); incorporating such markers
may also allow for greater parsimony of included variables.8
As well, feasibility of general population screening with these
tools remains uncertain. Thus, identifying patient populations
at highest risk for incident HF in whom targeted therapeutic
intervention would be expected to reduce such risk would
be welcome.
In contrast to challenges in screening general populations
for risk of incident HF, it may be possible to identify patient
groups at particularly high risk for incident HF. Horne and
colleagues described value of a risk score for predicting
incident HF in patients undergoing coronary angiography;9
however, this score lacked speciﬁc cardiac biomarkers. Sub-
sequently, Kleber and colleagues demonstrated that von
Willebrand factor and NT-proBNP improved risk prediction
in patients with HF with preserved ejection fraction under-
going coronary angiography.10 Similarly, Koller and col-
leagues found C-reactive protein to be an independent
predictor of mortality in patients with HF with preserved
ejection fraction undergoing coronary angiography.11 Ac-
cordingly, in the present post hoc analysis, we sought to
identify clinical and biomarker predictors of new-onset HF
in patients undergoing coronary and/or peripheral angiogra-
phy enrolled in the Catheter Sampled Blood Archive in
Cardiovascular Diseases (CASABLANCA; clinical trials.gov
NCT00842868) study.12 We hypothesized that the combina-
tion of clinical and circulating plasma biomarkers would pro-
vide accuracy of predicting new-onset HF and therapeutic
interventions might be useful to reduce such risk.
Methods
All study procedures were approved by the Partners
Healthcare Institutional Review Board and carried out in ac-
cordance with the Declaration of Helsinki.
Study design and participants
The design of the CASABLANCA study has been described pre-
viously.12 Brieﬂy, 1251 patients undergoing coronary and/or
peripheral angiography with or without intervention between
2008 and 2011 were prospectively enrolled at the Massachu-
setts General Hospital in Boston, MA. Patients were referred
for angiography for various acute and non-acute indications in-
cluding acute coronary syndromes, HF, abnormal stress tests,
stable chest pain, claudication, and routine pre-operative eval-
uation. Of the 1251 patients enrolled, 991 patients were free
of prevalent HF as identiﬁed by the combination of past
medical history and hospital records taken at the time of study
enrolment. Prevalent HF was identiﬁed on the basis of self-
report, and/or clinician identiﬁed diagnosis using standard
diagnostic criteria as outlined in HF management guidelines.13
Data acquisition
After informed consent was obtained, detailed clinical and his-
torical variables and reason for referral for coronary and/or
peripheral angiography were recorded using a standardized
case report form at the time of the angiographic procedure.
Follow-up
Medical record review from time of enrolment to end of
follow-up was performed. Median follow-up was 3.8 years
with a maximum follow-up of 8 years. For identiﬁcation of
clinical endpoints, review of medical records as well as phone
follow-up with patients and/or managing physicians was
performed. The Social Security Death Index and/or postings
of death announcements were used to conﬁrm vital status. A
detailed deﬁnition of endpoints for CASABLANCA was previ-
ously published.12 Speciﬁc to this analysis, new-onset HF was
deﬁned as signs and symptoms of HF in a patient without a pre-
vious diagnosis of chronic HF and at least one of the following:
(i) initiation or increase in dosage of diuretic or (ii) radiographic
evidence for pulmonary congestion or (iii) structural heart
disease with documentation of left ventricular ejection frac-
tion <40% or (iv) diastolic dysfunction or (v) BNP ≥400 pg/mL
or NT-proBNP according to age <50 years, ≥450 pg/mL;
50–75 years, ≥900 pg/mL; >75 years, ≥1800 pg/mL.14 For
any recurring events, each discrete event was recorded.
Biomarker testing
A total of 15 mL of blood was obtained immediately before the
angiographic procedure through a centrally placed vascular ac-
cess sheath. The blood was immediately centrifuged for
15 min, serum and plasma aliquoted on ice, and frozen at
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80 °C until biomarker measurement. The samples for this
study were analysed after the ﬁrst freeze–thaw cycle for base-
line biomarker values only. Testing for NT-proBNP was per-
formed on an automated platform (Dimension VISTA;
coefﬁcient of variation = 1.7% at 120 ng/L, 1.1% at 438 ng/L,
1.8% at 5075 ng/L; limit of detection, 0.8 ng/L), while ST2
was measured using a research assay (Presage ST2, Critical Di-
agnostics, San Diego, CA, USA) on an automated enzyme-linked
immunosorbent assay platform. This assay has a coefﬁcient of
variation of 2.0%, with values<35 pg/mL considered normal.15
Statistical analysis
The CASABLANCA patients selected for this analysis consisted
of 991 patients free of prevalent HF at baseline assessment.
These patients were referred for coronary and/or peripheral
angiography for various acute and non-acute indications.
Baseline characteristics between those with and without
new-onset HF were compared; dichotomous variables were
compared using χ2 or Fisher’s exact test, while continuous
variables were compared using Kruskal–Wallis test.
We ﬁrst used Cox proportional hazards model to assess the
relationship between each individual predictor and adjudi-
cated diagnosis of new-onset HF from a list of pre-selected co-
variates. We then included the covariates signiﬁcant at α level
of 0.10 into stepwise Cox proportional hazard models (using α
level of 0.10 for both entry and retain) to develop a prediction
model. Model discrimination and reclassiﬁcation (categorical
net reclassiﬁcation improvement and integrated discrimina-
tion improvement) with and without biomarkers were evalu-
ated. The ﬁnal model included heart rate, history of atrial
ﬁbrillation/ﬂutter, history of hypertension, and NT-proBNP
and ST2 concentrations; age and sex were forced into the
model. We then used the ﬁnal model to develop a risk score
for the new-onset HF.16 NT-proBNP was log-transformed for
the Cox model but dichotomized at 1000 pg/mL for the HF risk
score; ST2 was dichotomized at 35 ng/mL. Age and heart rate
were considered in deciles in the scoring system.
Cox proportional hazard models were used to predict the
risk of new-onset HF as a function of the HF risk score divided
into quintiles. Patients who did not experience an event were
censored at the time of last contact or at the time of death.
Comparison between time-to-event curves was made using
the log-rank test.
Cox models by the quintile of HF risk score was stratiﬁed
by guideline-directed medical therapy (GDMT) including
angiotensin-converting enzyme inhibitor (ACEi), angiotensin
receptor blocker (ARB), and beta-blocker. The number of pa-
tients on aldosterone antagonists was small, and therefore,
we were unable to run the model stratiﬁed by treatment with
aldosterone antagonists.
For the purpose of internal validation, the observed vs. pre-
dicted risk deciles for the HF risk model was tested using the
Hosmer–Lemeshow χ2 test. Additionally, bootstrapping was used
to internally validate the performance of the HF risk model.17
In all statistical analyses, a two-tailed P value of <0.05 was
considered statistically signiﬁcant. All analyses were per-
formed using the SAS Version 9.4.
Results
A study ﬂow for the present analysis is detailed in Figure 1.
Following the removal of patients with prevalent HF at the
time of enrolment, the study sample was 991 patients. Of
these, 177 (17.9%) developed new-onset HF following
enrolment.
Baseline characteristics
Baseline characteristics as a function of patients who
developed incident HF and those who did not are detailed in
Table 1. Patients with new-onset HF not surprisingly had prev-
alent risk factors for the diagnosis; they were more likely to be
older and to have a history of arrhythmia, hypertension, coro-
nary artery disease, diabetes mellitus, and chronic kidney
Figure 1 Study ﬂow diagram.
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Table 1 Baseline characteristics dichotomized by development of new-onset HF during follow-up
Characteristics Subjects with new-onset HF (N = 177) Subjects without HF (N = 814) P-value
Demographic
Age—mean ± SD 69.9 ± 11.9 65.3 ± 11.2 <0.001
Male sex 74.6% (132) 69.8% (568) 0.20
Caucasian 91.5% (162) 93.2% (759) 0.44
Vital signs
Heart rate (beats per min)
Mean ± SD 71.1 ± 14.5 (173) 67.8 ± 12.7 (786) 0.006
Systolic blood pressure (mmHg)
Mean ± SD 140.7 ± 23.4 (174) 138.2 ± 22.6 (792) 0.19
Diastolic blood pressure (mmHg)
Mean ± SD 73.3 ± 12.2 (174) 72.8 ± 11.3 (792) 0.58
Medical history
Smoker 14.8% (26/176) 15.7% (126/805) 0.77
Atrial ﬁbrillation/ﬂutter 24.3% (43) 10.1% (82) <0.001
Hypertension 86.4% (153) 72.5% (590) <0.001
Coronary artery disease 58.2% (103) 48.2% (392) 0.02
Prior myocardial infarction 24.3% (43) 18.8% (153) 0.10
Peripheral artery disease 36.2% (64) 22.7% (185) <0.001
COPD 25.6% (45/176) 14.1% (115) <0.001
Diabetes type I/type II 37.3% (66) 22.6% (184) <0.001
CVA/TIA 15.3% (27) 9.2% (75) 0.02
CKD 22.6% (40) 8.0% (65) <0.001
Renal replacement therapy 7.3% (13) 1.9% (15) <0.001
Prior angioplasty 17.5% (31) 11.8% (96) 0.04
Prior stent 36.2% (64) 30.2% (246) 0.12
Prior CABG 28.3% (50) 17.9% (146) 0.002
Medications
ACEi/ARB 60.8% (107/176) 49.6% (402/811) 0.007
Beta-blocker 76.3% (135) 66.9% (543/811) 0.02
Aldosterone antagonist 3.9% (7) 3.1% (25/811) 0.55
Loop diuretics 24.9% (44) 8.3% (67/811) <0.001
Nitrates 24.9% (44) 17.4% (141/810) 0.02
CCB 37.9% (67) 23.8% (193/811) <0.001
Statin 76.3% (135) 72.5% (587/810) 0.30
Aspirin 78.0% (138) 80.3% (651/811) 0.49
Warfarin 15.9% (28/176) 8.1% (66/811) 0.001
Clopidogrel 21.6% (38/176) 25.4% (206/811) 0.29
Cardiac tests
LVEF (%)
Echo—mean ± SD 56.8 ± 14.2 (107) 61.2 ± 11.7 (309) 0.005
Stress test—mean ± SD 56.4 ± 11.7 (33) 59.9 ± 12.0 (195) 0.12
RVSP by echo (mmHg)—mean ± SD 43.0 ± 12.3 (68) 38.4 ± 10.2 (150) 0.004
Mitral regurgitation <0.001
Trace 33.8% (24/71) 54.5% (110/202)
Mild 42.3% (30/71) 28.2% (57/202)
Moderate 19.7% (14/71) 6.9% (14/202)
Severe 1.4% (1/71) 2.5% (5/202)
Aortic insufﬁciency 0.07
Trace 49.3% (34/69) 41.5% (78/188)
Mild 13.0% (9/69) 7.5% (14/188)
Moderate 2.9% (2/69) 1.6% (3/188)
Severe 1.5% (1/69) 0.0% (0/188)
Aortic valve area <1.0 cm 25.0% (11/44) 25.2% (27/107) 0.98
Tricuspid regurgitation <0.001
Trace 72.2% (52/72) 83.4% (161/193)
Mild 25.0% (18/72) 8.3% (16/193)
Moderate 2.8% (2/72) 1.0% (2/193)
Angiography results
≥30% coronary stenosis ≥2 vessels 67.8% (101/149) 59.1% (424/717) 0.05
≥30% coronary stenosis ≥3 vessels 57.0% (85/149) 41.7% (299/717) <0.001
≥50% coronary stenosis ≥2 vessels 57.7% (86/149) 46.9% (336/717) 0.02
≥50% coronary stenosis ≥3 vessels 41.6% (62/149) 25.9% (186/717) <0.001
≥70% coronary stenosis ≥2 vessels 47.6% (71/149) 34.0% (244/717) 0.002
≥70% coronary stenosis ≥3 vessels 24.8% (37/149) 15.8% (113/717) 0.008
Lab measures
Creatinine (mg/dL)—mean ± SD (N) 1.7 ± 1.7 (158) 1.2 ± 0.7 (675) <0.001
(Continues)
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disease (CKD). Patients who developed new-onset HF were
more likely to be taking GDMT for HF, including ACEi/ARB,
beta-blocker, and loop diuretic, compared with those who
did not develop HF. The indications for diagnostic coronary an-
giography were similar between both groups; however, more
patients who developed new-onset HF had a primary indica-
tion of shortness of breath for coronary angiography, andmore
patients who had a primary indication of an abnormal stress
test for coronary angiography did not go on to develop new-
onset HF (Table 1).
Among those with echocardiographic data at presentation,
those with new-onset HF were more likely to have a lower left
ventricular ejection fraction when assessed by echocardiogra-
phy (56.8 ± 14.2% vs. 61.2 ± 11.7%, P = 0.005). Baseline aortic
valve disease was similar in the two groups, Presence of
mitral and tricuspid valve disease did not consistently predict
development of new-onset HF (Table 1). Baseline blood
pressure was not different between the two groups, but
those who developed new-onset HF had a higher baseline
heart rate (71.1 ± 14.5 vs. 67.8 ± 12.7, P = 0.006). Those with
new-onset HF were also more likely to have an elevated right
ventricular systolic pressure compared with those without
HF (43.0 ± 12.3 mmHg vs. 38.4 ± 10.2 mmHg, P = 0.004). Addi-
tionally, they had worse renal function compared with those
without HF. Multiple prognostic biomarkers were abnormal
at baseline in those with new-onset HF, including higher con-
centrations of highly sensitive troponin I, NT-proBNP, cystatin
C, myeloperoxidase, and ST2.
Predicting incident HF
Starting with 16 variables in univariate analyses, we then
performed multivariable modelling to identify independent
predictors of incident HF. These included clinical variables (heart
rate, history of atrial ﬁbrillation/ﬂutter, and history of hyperten-
sion) and concentrations of two biomarkers (NT-proBNP and
ST2). Age and sex were forced into the ﬁnal multivariable HF risk
prediction model (Table 2). In development of the HF risk score,
age and heart rate were considered in deciles and weighed
accordingly; NT-proBNP was dichotomized at 1000 pg/mL,18
and ST2 was dichotomized at 35 ng/mL19 (Table 3).
The c-statistic for the HF risk score model without bio-
markers was 0.69; including biomarkers signiﬁcantly in-
creased the c-statistic to 0.76 (P < 0.0001). Biomarkers also
signiﬁcantly reclassiﬁed risk for new-onset HF beyond clinical
Table 1 (continued)
Characteristics Subjects with new-onset HF (N = 177) Subjects without HF (N = 814) P-value
CKD-EPI eGFR—mean ± SD (N) 75.7 ± 30.2 (173) 96.2 ± 25.5 (802) <0.001
Haemoglobin (g/dL)—median (Q1, Q3) 12.8 (11.5, 14.1) 13.4 (12.3, 14.5) <0.001
Baseline biomarkers
MPO (pmol/L)—median (Q1, Q3) 459.3 (334.2, 640.0) 405.1 (309.3, 580.1) 0.01
hsTnI (pg/mL)—median (Q1, Q3) 11.7 (5.6, 40.8) 5.7 (2.9, 18.2) <0.001
NT-ProBNP (pg/mL)—median (Q1, Q3) 955.0 (299.0, 2514.0) 199.0 (79.0, 560.0) <0.001
Cystatin C (mg/L)—median (Q1, Q3) 1.0 (0.8, 1.2) 0.8 (0.7, 0.9) <0.001
ST2 (ng/mL)—median (Q1, Q3) 41.5 (31.1, 58.1) 34.9 (26.8, 46.4) <0.0001
Indications for catheter: presenting symptoms
Shortness of breath 32.2% (57/177) 15.4% (125/814) <0.001
AMI 6.2% (11/177) 8.7% (71/814) 0.27
UAP 8.5% (15/177) 12.4% (101/814) 0.14
Symptoms with positive imaging/stress test 31.07% (55/177) 41.2% (335/814) 0.01
Chest pain without or with negative imaging 15.3% (27/177) 17.8% (145/814) 0.42
Arrhythmia evaluation 6.2% (11/177) 3.9% (32/812) 0.18
Transplant coronary evaluation 0.6% (1/177) 0.6% (5/814) 0.94
Claudication 10.2% (18/177) 8.7% (71/812) 0.55
Hypertension 3.4% (6/177) 2.6% (21/814) 0.55
Carotid stenosis with TIA/CVA 0.6% (1/177) 0.3% (2/814) 0.48
Carotid stenosis without TIA/CVA 0.6% (1/177) 1.1% (9/812) 0.51
Other PAD without claudication 2.8% (5/177) 2.7% (22/813) 0.93
Pre-operative evaluation 10.2% (18/177) 10.9% (89/814) 0.77
ACEi, angiotensin-converting enzyme inhibitor; AMI, acute myocardial infarction; ARB, angiotensin receptor blocker; CABG, coronary ar-
tery bypass graft; CCB, calcium channel blocker; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CVA, cerebro-
vascular accident; eGFR, estimated glomerular ﬁltration rate; EPI, epidemiology; hsTnI, high sensitivity troponin I; LVEF, left ventricular
ejection fraction; MPO, myeloperoxidase; NT-proBNP, N-terminal pro B-type natriuretic peptide; PAD, peripheral artery disease; RVSP, right
ventricular systolic pressure; SD, standard deviation; TIA, transient ischaemic attack; UAP, unstable angina pectoris.
Patients developing incident HF showed numerous differences at baseline.
Table 2 Predictors of new-onset HF; age and sex were forced into
the model
Variables Hazard ratio (95% CI) P-value
Age 1.01 (1.00, 1.03) 0.11
Sex 1.79 (1.20, 2.68) 0.005
Heart rate 1.01 (1.00, 1.03) 0.045
History of atrial ﬁbrillation/ﬂutter 1.59 (1.06, 2.37) 0.02
History of hypertension 1.77 (1.09, 2.85) 0.02
Log-transformed NT-proBNP 1.55 (1.39, 1.73 <0.0001
ST2 ≥ 35 ng/mL 1.46 (1.01, 2.13) 0.046
CI, conﬁdence interval; NT-proBNP, N-terminal pro B-type natri-
uretic peptide.
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variables (net reclassiﬁcation improvement 0.26; integrated
discrimination improvement 0.10; both P < 0.0001).
As shown in the Supporting Information, Table S1, we
found direct association between risk for incident HF and
higher risk scores. When the HF risk score was divided into
quintiles, patients in the highest quintile had the highest inci-
dence of development of new-onset HF compared with those
with scores in lower quintiles (Figure 2).
Comparison of the observed vs. predicted risk deciles for
the HF risk score model using Hosmer–Lemeshow testing in-
dicates good model calibration (P = 0.12). We then internally
validated the modelling using 100 bootstrap iterations, which
yielded a Harrell’s c-statistic of 0.77.
Guideline-directed medical therapy, risk scores,
and incident HF
Cox models by the quintile of HF risk score were stratiﬁed by
GDMT with ACEi/ARB and beta-blocker. Patients in the highest
quintiles had the highest risk of development of new-onset HF,
and those not taking an ACEi/ARB or a beta-blocker had a higher
risk of developing new-onset HF compared with those taking an
ACEi/ARB or a beta-blocker (Table 4). The number of patients on
aldosterone antagonists was small, and therefore, we were
unable to run the model stratiﬁed by aldosterone antagonists.
Discussion
In the CASABLANCA study of patients without prevalent HF
undergoing coronary and/or peripheral angiography for both
acute and non-acute indications, we found a high risk for
progression on to development of symptomatic HF with
nearly 20% of those without prevalent HF developing the






















History of atrial ﬁbrillation Yes 3
Noa 0
History of hypertension Yes 4
Noa 0
NT-proBNP ≥ 1000 pg/mL Yes 6
Noa 0
ST2 ≥ 35 ng/mL Yes 3
Noa 0
NT-proBNP, N-terminal pro B-type natriuretic peptide.
Relative weight for each category is shown.
aReference category.
Figure 2 Time to ﬁrst HF event based on quintiles of risk score. Patients in the highest score quintile had the shortest time to development of incident HF.
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adjudicated diagnosis within 4 years after index procedure.
Following, we identiﬁed predictors of incident HF during this
follow-up period; from this, we developed a novel scoring
system to predict new-onset HF that consisted of a
combination of clinical variables (age, sex, heart rate, history
of atrial ﬁbrillation/ﬂutter, and history of hypertension) and
concentrations of two pathophysiologically distinct and im-
portant biomarkers (NT-proBNP and ST2). Higher scores cor-
related with a higher risk of development of new-onset HF.
Notably, those in the highest quintiles not prescribed GDMT
with ACEi/ARB or beta-blocker at the time of assessment
had a higher risk of development of new-onset HF compared
with those taking these medications. While most studies of
risk scores in disease processes are undermined by lack of ac-
tionable therapeutic information, this non-randomized obser-
vation suggests our risk model may not only identify risk for
HF onset, but it may also predict beneﬁt from aggressive ap-
plication of therapies to reduce such risk.
Prior studies have shown value of combining clinical vari-
ables with biomarkers to more accurately discriminate risk
for future HF. Agarwal and colleagues added NT-proBNP to a
pre-existing 10 year new-onset HF risk prediction score in
the Atherosclerosis Risk in Communities study, improving the
performance of the score;8 amodel restricted to age, sex, race,
and NT-proBNP alone was comparable with scores with a
greater number of variables. In a study by Brouwers and col-
leagues, 8569 patients without HF were categorized into high
and low risk on the basis of cardiovascular history, and the
prognostic value of 13 biomarkers reﬂecting diverse patho-
physiologic pathways was evaluated; risk stratiﬁcation in-
creased the incremental value per biomarker to predict new-
onset HF, especially in patients with HF with reduced ejection
fraction.20 In another study by Wannamethee and colleagues
of 3870 men aged 60–79 years not diagnosed with HF, NT-
proBNP was associated with HF in those with and without
established cardiovascular disease.21 Such ﬁndings illustrate
that perhaps biomarkers would improve discrimination, cali-
bration, and portability of new-onset HF risk prediction scores.
We found that concentrations of two biomarkers with a
broad knowledge base in those with established HF (NT-
proBNP and ST2) added considerably to clinical variables to
predict incident HF. The importance of biomarkers in the diag-
nosis and prognostication of prevalent HF is widely recognized;
however, the potential role of biomarkers to supplement clin-
ical variables to predict onset of HF in those without prevalent
HF is less widely accepted. Our data suggest in this particularly
at-risk population that the combination of both NT-proBNP (a
biomarker reﬂecting cardiomyocyte strain) and ST2 (amember
of the interleukin-1 receptor family released under conditions
of cardiovascular stress) adds independent prognostic value.
The addition of biomarkers to clinical factors substantially im-
proved model discrimination and reclassiﬁed risk for new-
onset HF beyond clinical variables alone. Although both
markers have been shown to predict HF events in those with
established HF syndromes, their role in patients such as those
in CASABLANCA is not as well determined. As well, several
other relevant biomarkers were not predictive of incident HF,
including highly sensitive troponin I, myeloperoxidase, and
measures of renal function (cystatin C and estimated glomeru-
lar ﬁltration rate).More patients who developed new-onset HF
had CKD or were on renal replacement therapy at baseline
(22.6% vs. 8.0% and 7.3% vs. 1.9%, P< 0.001 for both, respec-
tively), and while underlying CKD is a well-known risk factor for
the development of HF, not all patients with CKD developed
new-onset HF. Furthermore, our HF score model was vigor-
ously adjusted to account for underlying renal dysfunction,
and while NT-proBNP concentrations may be affected by un-
derlying CKD, data suggest that when elevated in patients with
CKD, NT-proBNP is more (rather than less) prognostic.22,23
A major advantage of our cohort is its detailed characteri-
zation and our experience working with this particular cohort
of patients. Our score is also clinically relevant and easily
Table 4 Predicting new-onset HF as a function of quintiles of HF risk score stratiﬁed by guideline-directed medical therapies
A
Quintiles of risk score Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
Taking ACEi/ARB Not taking ACEi/ARB
Quintile 1 Reference Reference
Quintile 2 0.62 (0.17, 2.30) 0.47 2.31 (0.82, 6.49) 0.11
Quintile 3 2.58 (0.88, 7.54) 0.08 2.51 (0.77, 8.23) 0.13
Quintile 4 2.32 (0.79, 6.80) 0.12 3.50 (1.31, 9.33) 0.01
Quintile 5 7.24 (2.62, 20.04) 0.0001 11.44 (4.75, 27.59) <0.0001
B
Taking beta-blocker Not taking beta-blocker
Quintile 1 Reference Reference
Quintile 2 1.05 (0.40, 2.77) 0.91 2.20 (0.49, 9.81) 0.30
Quintile 3 2.77 (1.16, 6.59) 0.02 4.08 (1.02, 16.30) 0.05
Quintile 4 2.52 (1.08, 5.87) 0.03 5.33 (1.47, 19.36) 0.01
Quintile 5 7.52 (3.44, 16.40) <0.0001 19.02 (5.52, 65.47) <0.0001
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CI, conﬁdence interval.
It is a noteworthy hazard for incident HF was higher in those not taking (A) ACEi/ARB or (B) beta-blockers.
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applicable. Although in the development of this HF risk score
our approach was methodical, limitations to our study exist.
The CASABLANCA cohort was predominantly male, Cauca-
sian, and representative of patients in a tertiary care referral
centre. Data regarding pre-existing underlying diastolic dys-
function are lacking as are data regarding whether atrial ﬁ-
brillation is persistent, both of which can predispose
patients to development of HF. More patients who devel-
oped new-onset HF were on diuretics, and while there are
several indications for use of loop diuretics other than HF,
we, unfortunately, do not have data regarding the indication
for treatment with loop diuretics. We concede that we possi-
bly detected a forme fruste of HF in some patients.
We did not have an external cohort to validate our score,
but internal validation testing returned consistent results;
we presently have plans to externally validate this score in
a distinct patient cohort. Additionally, because the patients
in our study were referred for coronary and/or peripheral an-
giography, the pre-test probability for development of new-
onset HF was higher than if a community-based cohort with-
out indications for invasive angiography was studied; we do
not feel this is a limitation, however, as such patients have
a substantial risk for HF onset, the very patients where ther-
apeutic intervention might be well expected to reduce hazard
substantially, as we found. Lastly, while therapies appear to
interact with our risk score—implying potential value from in-
tervention in those at highest risk—we lack data regarding
doses of GDMT applied, and we do not have serial measure-
ment of clinical variables, medication therapy, or biomarkers
to see if changes in treatment over time modify risk score re-
sults and/or inﬂuence subsequent predicted risk for HF onset.
Appropriate attention has been given to the identiﬁcation
and optimal management of patients at high risk for symptom-
atic HF (i.e. those with Stages A and B HF5). Study participants
in CASABLANCA indeed reﬂect such patients, and our data sug-
gest the ability to accurately detect those at highest risk for on-
set of HF. This is of some interest, and such data might be
useful to inform clinical trial design or even be applied as inclu-
sion criteria in trials of therapies that might reduce HF risk. On
a clinical utility level, however, as most risk scores do not have a
therapeutic imperative, we felt it important to further explore
how GDMT for HF might inﬂuence subsequent onset of HF in
those judged at highest risk. In this, we found lower observed
HF onset in those predicted as higher risk treated with GDMT.
This ﬁnding is a substantial difference from many studies de-
scribing risk scores, which tend to lack guidance regarding
how results might be used to optimize patient management.
More data regarding interaction between our score and other
HF GDMT options, including sacubitril/valsartan, are warranted.
In conclusion, we have developed a clinical and biomarker
score to predict incident HF in an at-risk population. This strat-
egy, using traditional variables available at the bedside together
with biomarker concentrations, is likely to provide a cost-
effective and widely available method to predict risk for incident
HF in patients commonly treated in cardiovascular medicine.
The potential to prevent HF onset through application of thera-
pies triggered/guided by this score deserves further exploration.
Conﬂict of interest
H.K.G. has received grant support from Roche and Portola;
consulting income from Roche Diagnostics, American Regent,
Amgen, Boston Heart Diagnostics, and Critical Diagnostics;
and research payments for clinical endpoint committees
for EchoSense. J.L.J. has received grant support from
Siemens, Singulex, and Prevencio and consulting income from
Roche Diagnostics, Critical Diagnostics, Sphingotec, Philips, and
Novartis and participates in clinical endpoint committees/data
safety monitoring boards for Novartis, Amgen, Janssen, and
Boehringer Ingelheim. Siemens Diagnostics, Inc., had no in-
volvement in the present study design, collection, analysis,
and interpretation of data; in the writing of the report; and
in the decision to submit the article for publication. The
remaining authors have nothing to disclose.
Funding
Siemens Diagnostics, Inc. to the CASABLANCA study; Dennis
and Marilyn Barry Fellowship in Cardiology to N.E.I., H.K.G.,
S.R.M. and P.U.G.; Ruth and James Clark Fund for Cardiac
Research Innovation to H.K.G.; and the Hutter Family
Professorship in Cardiology to J.L.J.
Supporting information
Additional Supporting Information may be found online in
the supporting information tab for this article.
Table S1. Risk for development of new-onset HF increased as
HF risk score increased.
References
1. Bhupathiraju SN, Hu FB. Epidemiology
of obesity and diabetes and their
cardiovascular complications. Circ Res
2016; 118: 1723–1735.
2. Mozaffarian D, Benjamin EJ, Go AS,
Arnett DK, Blaha MJ, Cushman M,
Predicting new-onset HF 247
ESC Heart Failure 2018; 5: 240–248
DOI: 10.1002/ehf2.12268
Das SR, de Ferranti S, Després J-P,
Fullerton HJ, Howard VJ, Huffman MD,
Isasi CR, Jiménez MC, Judd SE,
Kissela BM, Lichtman JH, Lisabeth LD,
Liu S, Mackey RH, Magid DJ, McGuire
DK, Mohler ER, Moy CS, Muntner P,
Mussolino ME, Nasir K, Neumar RW,
Nichol G, Palaniappan L, Pandey DK,
Reeves MJ, Rodriguez CJ, Rosamond
W, Sorlie PD, Stein J, Towﬁghi A,
Turan TN, Virani SS, Woo D, Yeh RW,
Turner MB. Heart Disease and Stroke
Statistics—2016 Update. A report from
the American Heart Association. 2016;
133: e38–e360.
3. Konstam MA, Desai AS. Home monitor-
ing should be the central element in an
effective program of heart failure dis-
ease management. Circulation 2012;
125: 820–827.
4. Desai AS. Home monitoring heart failure
care does not improve patient outcomes:
looking beyond telephone-based disease
management. Circulation 2012; 125:
828–836.
5. Yancy CW, Jessup M, Bozkurt B, Butler J,
Casey DE, Drazner MH, Fonarow GC,
Geraci SA, Horwich T, Januzzi JL,
Johnson MR, Kasper EK, Levy WC,
Masoudi FA, McBride PE, McMurray JJV,
Mitchell JE, Peterson PN, Riegel B, Sam
F, Stevenson LW, Tang WHW, Tsai EJ,
Wilkoff BL. 2013 ACCF/AHA guideline
for the management of heart failure: ex-
ecutive summary: a report of the Amer-
ican College of Cardiology
Foundation/American Heart Association
Task Force on Practice Guidelines. J
Am Coll Cardiol 2013; 62: 1495–1539.
6. Kannel WB, D’Agostino RB, Silbershatz
H, Belanger AJ,Wilson PF, LevyD. Proﬁle
for estimating risk of heart failure. Arch
Intern Med 1999; 159: 1197–1204.
7. Butler J, Kalogeropoulos A,
Georgiopoulou V, Belue R, Rodondi N,
Garcia M, Bauer DC, Satterﬁeld S, Smith
AL, Vaccarino V, Newman AB, Harris TB,
Wilson PWF, Kritchevsky SB. Incident
heart failure prediction in the elderly:
the health ABC heart failure score. Circ
Heart Fail 2008; 1: 125–133.
8. Agarwal SK, Chambless LE, Ballantyne
CM, Astor B, Bertoni AG, Chang PP,
Folsom AR, He M, Hoogeveen RC, Ni H,
Quibrera M, Rosamond WD, Russell SD,
Shahar E, Heiss G. Prediction of incident
heart failure in general practice: the ARIC
study. Circulation: Heart Failure 2012.
9. Horne BD, May HT, Kfoury AG, Renlund
DG, Muhlestein JB, Lappé DL,
Rasmusson KD, Bunch TJ, Carlquist JF,
Bair TL, Jensen KR, Ronnow BS,
Anderson JL. The Intermountain Risk
Score (including the red cell distribution
width) predicts heart failure and other
morbidity endpoints. Eur J Heart Fail
2010; 12: 1203–1213.
10. Kleber ME, Koller L, Goliasch G,
Sulzgruber P, Scharnagl H, Silbernagel
G, Grammer TB, Delgado G, Tomaschitz
A, Pilz S, März W, Niessner A. Von
Willebrand factor improves risk
prediction in addition to N-terminal
pro–B-type natriuretic peptide in
patients referred to coronary angiogra-
phy and signs and symptoms of heart
failure and preserved ejection fraction.
Circ Heart Fail 2015; 8: 25–32.
11. Koller L, Kleber M, Goliasch G,
Sulzgruber P, Scharnagl H, Silbernagel
G, Grammer T, Delgado G, Tomaschitz
A, Pilz S, März W, Niessner A. C-reactive
protein predicts mortality in patients re-
ferred for coronary angiography and
symptoms of heart failure with pre-
served ejection fraction. Eur J Heart Fail
2014; 16: 758–766.
12. Gaggin HK, Bhardwaj A, Belcher A,
Motiwala S, Gandhi PU, Simon M, Kelly
N, Anderson A, Garasic JM, Danik S,
Schwamm LH, Gerszten RE, van
Kimmenade R, Januzzi J. Design,
methods, baseline characteristics and in-
terim results of the Catheter Sampled
Blood Archive in Cardiovascular Dis-
eases (CASABLANCA) study. IJC of Met-
abolic & Endocrine 2014; 5: 11–18.
13. Ponikowski P, Voors AA, Anker SD, Bueno
H, Cleland JGF, Coats AJS, Falk V,
González-Juanatey JR, Harjola V-P,
Jankowska EA, Jessup M, Linde C,
Nihoyannopoulos P, Parissis JT, Pieske B,
Riley JP, Rosano GMC, Ruilope LM,
Ruschitzka F, Rutten FH, van der Meer P,
Filippatos G, McMurray JJV, Aboyans V,
Achenbach S, Agewall S, Al-Attar N, Ath-
erton JJ, Bauersachs J, John Camm A,
Carerj S, Ceconi C, Coca A, Elliott P, Erol
Ç, Ezekowitz J, Fernández-Golfín C,
Fitzsimons D, Guazzi M, Guenoun M,
Hasenfuss G, Hindricks G, Hoes AW, Iung
B, Jaarsma T, Kirchhof P, Knuuti J, Kolh P,
Konstantinides S, Lainscak M, Lancellotti
P, Lip GYH, Maisano F, Mueller C, Petrie
MC, Piepoli MF, Priori SG, Torbicki A,
Tsutsui H, van Veldhuisen DJ, Windecker
S, Yancy C, Zamorano JL, Zamorano JL,
Aboyans V, Achenbach S, Agewall S,
Badimon L, Barón-Esquivias G,
Baumgartner H, Bax JJ, Bueno H, Carerj
S, Dean V, Erol Ç, Fitzsimons D, Gaemperli
O, Kirchhof P, Kolh P, Lancellotti P, Lip
GYH, Nihoyannopoulos P, Piepoli MF,
Ponikowski P, Rofﬁ M, Torbicki A, Vaz
Carneiro A, Windecker S, Sisakian HS,
Isayev E, Kurlianskaya A, Mullens W,
Tokmakova M, Agathangelou P,
Melenovsky V, Wiggers H, Hassanein M,
Uuetoa T, Lommi J, Kostovska ES, Juillière
Y, Aladashvili A, Luchner A, Chrysohoou
C, Nyolczas N, Thorgeirsson G, Marc
Weinstein J, Di Lenarda A, Aidargaliyeva
N, Bajraktari G, Beishenkulov M, Kamzola
G, Abdel-Massih T, Čelutkienė J, Noppe S,
Cassar A, Vataman E, Abir-Khalil S, van
Pol P, Mo R, Straburzyńska-Migaj E,
Fonseca C, Chioncel O, Shlyakhto E,
Otasevic P, Goncalvesová E, Lainscak M,
Díaz Molina B, Schaufelberger M, Suter
T, Yılmaz MB, Voronkov L, Davies C.
2016 ESC Guidelines for the diagnosis
and treatment of acute and chronic heart
failure: The Task Force for the diagnosis
and treatment of acute and chronic heart
failure of the European Society of Cardiol-
ogy (ESC). Developed with the special
contribution of the Heart Failure Associa-
tion (HFA) of the ESC. Eur Heart J 2016;
37: 2129–2200.
14. Januzzi JL Jr, Sakhuja R, O’Donoghue M,
Baggish AL, Anwaruddin S, Chae CU,
Cameron R, Krauser DG, Tung R,
Camargo CAJ, Lloyd-Jones DM. Utility
of amino-terminal pro-brain natriuretic
peptide testing for prediction of 1-year
mortality in patients with dyspnea
treated in the emergency department.
Arch Intern Med 2006; 166: 315–320.
15. Dieplinger B, Januzzi JL Jr, Steinmair M,
Gabriel C, Poelz W, Haltmayer M,
Mueller T. Analytical and clinical evalu-
ation of a novel high-sensitivity assay
for measurement of soluble ST2 in hu-
man plasma—the Presage™ ST2 assay.
Clin Chim Acta 2009; 409: 33–40.
16. Sullivan LM,Massaro JM, D’Agostino RB.
Presentation of multivariate data for
clinical use: the Framingham Study risk
score functions. Stat Med 2004; 23:
1631–1660.
17. Miao Y, Cenzer IS, Kirby KA, BoscardinWJ.
Estimating Harrell’s optimism on predic-
tive indices using bootstrap samples. SAS
Global Forum 2013(504–2013).
18. Kim H-N, Januzzi JL. Natriuretic peptide
testing in heart failure. Circulation 2011;
123: 2015–2019.
19. Januzzi JL, Pascual-Figal D, Daniels LB.
ST2 testing for chronic heart failure
therapy monitoring: the International
ST2 Consensus Panel. Am J Cardiol
2015; 115: 70B–75B.
20. Brouwers FP, van Gilst WH, Damman K,
van den Berg MP, Gansevoort RT,
Bakker SJL, Hillege HL, van Veldhuisen
DJ, van der Harst P, de Boer RA. Clinical
risk stratiﬁcation optimizes value of bio-
markers to predict new-onset heart fail-
ure in a community-based cohort. Circ
Heart Fail 2014; 7: 723–731.
21. Goya Wannamethee S, Welsh P,
Whincup PH, Lennon L, Papacosta O,
Sattar N. N-terminal pro brain natri-
uretic peptide but not copeptin improves
prediction of heart failure over other
routine clinical risk parameters in older
men with and without cardiovascular
disease: population-based study. Eur J
Heart Fail 2014; 16: 25–32.
22. Anwaruddin S, Lloyd-Jones DM,
Baggish A, Chen A, Krauser D, Tung R,
Chae C, Januzzi JL. Renal function,
congestive heart failure, and amino-
terminal pro-brain natriuretic peptide
measurement: results from the proBNP
investigation of dyspnea in the
emergency department (PRIDE) study.
J Am Coll Cardiol 2006; 47: 91–97.
23. van Kimmenade RRJ, Januzzi JL,
Baggish AL, Lainchbury JG, Bayes-Genis
A, Richards AM, Pinto YM. Amino-
terminal pro-brain natriuretic peptide,
renal function, and outcomes in acute
heart failure: redeﬁning the cardiorenal
interaction? J Am Coll Cardiol 2006;
48: 1621–1627.
248 N.E. Ibrahim et al.
ESC Heart Failure 2018; 5: 240–248
DOI: 10.1002/ehf2.12268
